|Bid||0.8911 x 800|
|Ask||0.8920 x 1100|
|Day's Range||0.8221 - 0.9100|
|52 Week Range||0.4700 - 2.5500|
|Beta (5Y Monthly)||1.62|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 12, 2021 - May 17, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||May 12, 1980|
|1y Target Est||N/A|
AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today noted that a recent study announced positive early results from a PSMA 617-Lu177 study conducted by a leading global pharmaceutical company. The report provides strong indications for analogous success in similar technology the Company is helping to develop.
AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that it has been granted an exclusive sublicense to technology related to the use of novel and proprietary central nervous system (CNS) homing peptides for the therapeutic treatment of neuroinflammatory disease in cancer patients.
AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided a business update.